News
Masimo Corporation's Mighty Momentum Continues in 3rd Quarter
Things looked so great for Masimo Corporation (NASDAQ: MASI) when it reported results from the second quarter in August that the company upped its full-year guidance. Revenue and earnings soared,....
Global Blood Therapeutics Inc. Jumped as Much as 14% on This News
Shares of San Francisco-based Global Blood Therapeutics (NASDAQ: GBT), a small-cap developer of experimental therapies focused on treating blood-based disorders, rocketed higher by as much as 14%....
The Clear Reason Alkermes Plc's Shares Jumped by as Much as 12%
Shares of Alkermes (NASDAQ: ALKS), an Irish-based commercial-stage drug developer with a focus on central nervous system medicines, jumped by as much as 12% during Thursday's trading session and....
Alkermes Reports Mixed Results, Updates Guidance
Alkermes (NASDAQ: ALKS), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, reported its third-quarter earnings results on Thursday, Oct. 26. While....
Here's Why NuVasive, Inc. Popped Today
Shares of NuVasive, Inc. (NASDAQ: NUVA), a spinal-surgery device manufacturer, popped as high as 9.8% Wednesday morning before settling back down to an 8.1% gain as of 3:07 p.m. A mixed....
Here's Why Acadia Healthcare Company Inc. Is Sinking Today
Shares of Acadia Healthcare Company Inc. (NASDAQ: ACHC) have fallen 25.6% as of 11:01 a.m. EDT on Wednesday after the company reported softer-than-expected results on Tuesday. The provider....
NuVasive's Sluggish Sales Growth Prompts Buybacks
Modern medicine has offered some revolutionary products and techniques, and many companies are looking to help sustain the pace of medical advances. NuVasive's (NASDAQ: NUVA) specialty in spinal....
3 Top Biotech Stocks to Buy Now
You should seriously consider adding a few biotech stocks to your portfolio if you don't already own some. Why? Because they give you an opportunity to make higher returns.And the good news is....
3 Arguments for and Against Legalizing Marijuana
There's arguably no industry in the U.S. that's growing at a faster, more consistent pace than legal marijuana. Marijuana Business Daily's latest report, "Marijuana Business Factbook 2017,"....
Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies Inc.
Biotech investors are always looking for the next big thing. That's exactly what they found in Exelixis (NASDAQ: EXEL), which ranked as one of the top biotech stocks of 2016 (and 2015 also). But....
Why uniQure N.V. Stock Is Hopping Today
Shares of the gene therapy company uniQure N.V. (NASDAQ: QURE) rose by as much as 27% in early-morning trading today on over 27 times the average volume. uniQure's stock is responding positively....
Why Marijuana Stocks Won't Pay a Dividend, Even if They're Profitable
There aren't too many industries that can grow at 20%-plus a year over the next five years, but marijuana could be one of them. Cannabis research firm ArcView believes the legal North American pot....
3 Small-Cap Biotech Stocks That Could Be Big Winners in 2018
Small-cap biotech stocks, or companies with valuations ranging from $300 million to $2 billion, can generate truly astonishing returns on capital in exceptionally short periods of time. Several of....
Why Exelixis' Rebound Is Just Getting Started
Exelixis (NASDAQ: EXEL) stock had been in the doldrums. After roaring for much of the first eight months of the year, the biotech's share price sank more than 15% during September. All of that is....
Where Will Opko Health Inc. Be in 5 Years?
Opko Health (NASDAQ: OPK) has had a rough year no matter how you look at it. So far in 2017, shares of the pharmaceutical and diagnostics company are down more than 20%. At one point, Opko stock....
Why Exelixis, Inc. Rose Higher Today
Exelixis (NASDAQ: EXEL) is up 24% at 12:21 p.m. EDT after announcing that the phase 3 Celestial trial met its primary endpoint of helping liver cancer patients taking Cabometyx live longer than....
3 Growth Stocks at Value Stock Prices
It's not surprising that after an eight-year bull market, some are saying value investing is dead. With the cyclically adjusted P/E ratio of the S&P running at a red-hot 31, finding a value....
3 Signs Myriad Genetics' High-Growth Days Are Over
Myriad Genetics (NASDAQ: MYGN) used to be the creme de la creme of the genetic testing industry. It had healthy profit margins, a growing business, and was well-known among investors and health....
Why CRISPR Therapeutics AG Stock Lost Ground in September
According to data from S&P Global Market Intelligence, shares of the gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) dropped by 13.1% in September. CRISPR's poor showing last month....
3 Monster Stocks in the Making
Halloween is right around the corner, which makes it the perfect time to look for monster stocks in the making. What are some characteristics these stocks might have? Leading market positions,....
Why Viacom, DaVita, and K2M Group Holdings Slumped Today
Monday was a down day on Wall Street, with the Dow, S&P 500, and Nasdaq Composite all giving up between 0.1% and 0.2%. The trading session was relatively quiet on the Columbus Day holiday,....
Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) continued its monster climb this year with a 10% gain in September, according to data from S&P Global Market Intelligence. Preclinical results....
Why PTC Therapeutics, Inc. Dropped Today
PTC Therapeutics (NASDAQ: PTCT) fell 10.9% on Tuesday after disclosing data for RG7916 in patients with Type 2 and Type 3 spinal muscular atrophy (SMA).It's been a roller coaster for PTC....
Fighting Debt Demons, Valeant Pharmaceuticals Just Priced a New Debt Offering
The theme of 2017 for embattled drug developer Valeant Pharmaceuticals (NYSE: VRX) is "baby steps." After a miserable 2015 and 2016, which saw the company get buried under debt and accused of....
Cantel Medical Corp. Closes Out the Year With a Solid Mix of Growth
Cantel Medical (NYSE: CMD) closed out its fiscal year that ended in July with a solid fourth quarter and looks to build on the year with impressive guidance for the fiscal year ahead. Here's a....